Pidilizumab
DLL1 | |
|---|---|
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6424H9920N1704O2002S48 |
| Molar mass | 144594.83 g·mol−1 |
Pidilizumab (formerly CT-011) is a monoclonal antibody being developed by
PD-1 is secondary and restricted to non-glycosylated and hypoglycosylated forms of this molecule.[3]
Pidilizumab causes in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory T cells.
Clinical trials
It had encouraging results by 2011 from phase II clinical trials for
diffuse intrinsic pontine glioma, found improvement in overall survival compared to expected outcome.[citation needed] An add-on trial for multiple myeloma is ongoing.[5]
References
- PMID 24332512.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Pidilizumab, American Medical Association- needs login.
- ^ Carroll J (26 January 2016). "Anti-PD-1? Well, no, says Medivation as a partial hold forces a halt to 'pivotal' cancer study". Fierce Biotech.
- ^ "Teva Invests $19M More in CureTech After Positive Phase II DLBCL Data". Genetic Engineering & Biotechnology News. September 2011.
- ^ Clinical trial number NCT02077959 for "Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma" at ClinicalTrials.gov
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |